108 related articles for article (PubMed ID: 38009667)
1. Genomic and immune landscape in hepatocellular carcinoma: Implications for personalized therapeutics.
Zheng J; Chen J; Wang S; Yang D; Zhou P
Environ Toxicol; 2024 Mar; 39(3):1601-1616. PubMed ID: 38009667
[TBL] [Abstract][Full Text] [Related]
2. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
3. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
4. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
[TBL] [Abstract][Full Text] [Related]
5. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
Liu Z; Zhao P
J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
[TBL] [Abstract][Full Text] [Related]
6. Novel Molecular Subtyping Scheme Based on In Silico Analysis of Cuproptosis Regulator Gene Patterns Optimizes Survival Prediction and Treatment of Hepatocellular Carcinoma.
Jiang H; Chen H; Wang Y; Qian Y
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762710
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
8. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
Wang S; Bai H; Fei S; Miao B
Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
[TBL] [Abstract][Full Text] [Related]
9. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
10. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma.
Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
Front Genet; 2023; 14():1056000. PubMed ID: 36845390
[No Abstract] [Full Text] [Related]
11. Identification and development of a novel risk model based on cuproptosis-associated RNA methylation regulators for predicting prognosis and characterizing immune status in hepatocellular carcinoma.
Li D; Shi Z; Liu X; Jin S; Chen P; Zhang Y; Chen G; Fan X; Yang J; Lin H
Hepatol Int; 2023 Feb; 17(1):112-130. PubMed ID: 36598701
[TBL] [Abstract][Full Text] [Related]
12. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
Chen X; Hu G; Xiong L; Xu Q
Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
[No Abstract] [Full Text] [Related]
13. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
Mo Z; Liu D; Rong D; Zhang S
Front Immunol; 2021; 12():611058. PubMed ID: 33679749
[No Abstract] [Full Text] [Related]
14. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
Yan C; Niu Y; Ma L; Tian L; Ma J
J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
[TBL] [Abstract][Full Text] [Related]
15. Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma.
Zhang Z; Zeng X; Wu Y; Liu Y; Zhang X; Song Z
Front Immunol; 2022; 13():925618. PubMed ID: 35898502
[TBL] [Abstract][Full Text] [Related]
16. Copper metabolism-related risk score identifies hepatocellular carcinoma subtypes and SLC27A5 as a potential regulator of cuproptosis.
Li X; Wang J; Guo Z; Ma Y; Xu D; Fan D; Dai P; Chen Y; Liu Q; Jiao J; Fan J; Wu N; Li X; Li G
Aging (Albany NY); 2023 Dec; 15(24):15084-15113. PubMed ID: 38157255
[TBL] [Abstract][Full Text] [Related]
17. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
18. Identification of a cuproptosis and copper metabolism gene-related lncRNAs prognostic signature associated with clinical and immunological characteristics of hepatocellular carcinoma.
Yuan W; Xiao JH; Zhang JS; Mao BL; Wang PZ; Wang BL
Front Oncol; 2023; 13():1153353. PubMed ID: 37056336
[TBL] [Abstract][Full Text] [Related]
19. An 8-gene predicting survival model of hepatocellular carcinoma (HCC) related to pyroptosis and cuproptosis.
Wang H; Wang N; Tang Z; Liu Q; Nie S; Tao W
Hereditas; 2023 Jul; 160(1):30. PubMed ID: 37464443
[TBL] [Abstract][Full Text] [Related]
20. Copper and cuproptosis-related genes in hepatocellular carcinoma: therapeutic biomarkers targeting tumor immune microenvironment and immune checkpoints.
Wang X; Chen D; Shi Y; Luo J; Zhang Y; Yuan X; Zhang C; Shu H; Yu W; Tian J
Front Immunol; 2023; 14():1123231. PubMed ID: 37153542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
